High-Dose Extended-Release Lansoprazole (Dexlansoprazole) and Amoxicillin Dual Therapy for Helicobacter pylori Infections

Helicobacter

Volumn 19, Issue 4, 2014, Pages 319-322

  Attumi, Taraq A ^a   Graham, David Y ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Amoxicillin; Clinical trial; Dexlansoprazole; Eradication therapy; Helicobacter pylori; Proton pump inhibitors

Indexed keywords

AMOXICILLIN; LANSOPRAZOLE; ANTIINFECTIVE AGENT; PROTON PUMP INHIBITOR; UREA;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DISEASE ERADICATION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; HELICOBACTER INFECTION; HUMAN; INCREASED APPETITE; INTENTION TO TREAT ANALYSIS; MALE; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH PAIN; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; UREA BREATH TEST; BREATH ANALYSIS; CLINICAL TRIAL; DRUG COMBINATION; ENZYMOLOGY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; METABOLISM; MIDDLE AGED; PROCEDURES;

HELICOBACTER PYLORI;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; BREATH TESTS; DEXLANSOPRAZOLE; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TREATMENT OUTCOME; UREA;

EID: 84904720421     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12126     Document Type: Article

References (34)

1. Borsch GM, Graham DY. Helicobacter pylori. In: Collen MJ, Benjamin SB, eds. Pharmacology of Peptic Ulcer Disease: Handbook of Experimental Pharmacology (vol. 99). Berlin: Springer-Verlag, 1991;107-48.
2. Unge P, Gad A, Gnarpe H, Olsson J. Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study. Scand J Gastroenterol Suppl 1989;167:49-54.
3. van der Hulst RW, Keller JJ, Rauws EA, Tytgat GN. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996;1:6-19.
4. Bazzoli F, Pozzato P, Zagari M, Fossi S, Ricciardiello L, Nicolini G, Berretti D, De Luca L. Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta- analysis. Helicobacter 1998;3:195-201.
5. Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 2007;56:475-9.
6. Sachs G, Meyer-Rosberg K, Scott DR, Melchers K. Acid, protons and Helicobacter pylori. Yale J Biol Med 1996;69:301-16.
7. Sachs G, Wen Y, Scott DR. Gastric infection by Helicobacter pylori. Curr Gastroenterol Rep 2009;11:455-61.
8. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008;5:321-31.
9. Attumi TA, Graham DY. Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study. J Gastroenterol Hepatol 2012;27:59-61.
10. Shirai N, Sugimoto M, Kodaira C, Nishino M, Ikuma M, Kajimura M, Ohashi K, Ishizaki T, Hishida A, Furuta T. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol 2007;63:743-9.
11. Bayerdorffer E, Miehlke S, Mannes GA, Sommer A, Hochter W, Weingart J, Heldwein W, Klann H, Simon T, Schmitt W. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995;108:1412-7.
12. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129:1027-30.
13. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Nakagawa K, Sugimura H, Ohashi K, Ishizaki T. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001;11:341-8.
14. Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, Ohashi K, Ishizaki T. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 2003;50:2274-8.
15. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007;81:521-8.
16. Sugimoto M, Furuta T, Shirai N, et al. Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert Opin Pharmacother 2007;8:2701-17.
17. Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Ikuma M, Shirai N. The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori. Hepatogastroenterology 2010;57:1314-9.
18. Emerson CR, Marzella N. Dexlansoprazole: a proton pump inhibitor with a dual delayed-release system. Clin Ther 2010;32:1578-96.
19. Metz DC, Vakily M, Dixit T, Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009;29:928-37.
20. Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009;25:627-38.
21. Ward MB, Foster DJ. CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualisation in H. pylori eradication. Eur J Clin Pharmacol 2010;67:261-6.
22. de Boer WA, Thys JC, Borody TJ, Graham DY, O'Morain C, Tytgat GN. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur J Gastroenterol Hepatol 1996;8:641-3.
23. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol 2009;7:145-8.
24. Atherton JC, Hudson N, Kirk GE, Hawkey CK, Spiller RC. Amoxycillin capsules with omeprazole for the eradication of Helicobacter pylori. Assessment of the importance of antibiotic dose timing in relation to meals. Aliment Pharmacol Ther 1994;8:495-8.
25. Atherton JC, Cullen DJ, Kirk GE, Hawkey CJ, Spiller RC. Enhanced eradication of Helicobacter pylori by pre- versus post-prandial amoxycillin suspension with omeprazole: implications for antibiotic delivery. Aliment Pharmacol Ther 1996;10:631-5.
26. Labenz J, Stolte M, Blum AL, Jorias I, Leverkus F, Sollbohmer M, Bertrams J, Borsch G. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995;37:39-43.
27. Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am 2010;39:465-80.
28. Graham DY, Javed SU, Keihanian S, Abudayyeh S, Opekun AR. Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol 2010;45:816-20.
29. Kim SY, Jung SW, Kim JH, Koo JS, Yim HJ, Park JJ, Chun HJ, Lee SW, Choi JH. Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea. Br J Clin Pharmacol 2012;73:140-3.
30. Labenz J, Leverkus F, Borsch G. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol 1994;29:1070-5.
31. Shiotani A, Graham DY. Pathogenesis and therapy of gastric and duodenal ulcer disease. Med Clin North Am 2002;86:1447-66, viii.
32. Bynum TE, Solomon TE, Johnson LR, Jacobson ED. Inhibition of pancreatic secretion in man by cigarette smoking. Gut 1972;13:361-5.
33. Hogan DL, Ainsworth MA, Isenberg JI. Review article: gastroduodenal bicarbonate secretion. Aliment Pharmacol Ther 1994;8:475-88.
34. Harford W, Lanza F, Arora A, Graham D, Haber M, Weissfeld A, Rose P, Siepman N. Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. Helicobacter 1996;1:243-50.